Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 20 clinical trials
Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients

tumor's HER2 is positive, the patient can receive targeted therapy (Herceptin) combined with tamoxifen or placebo. The follow-up time will be eight years. The aim of this trial is to evaluate the

metastasis
mastectomy
axillary lymph node dissection
HER2
sentinel node
  • 30 views
  • 18 May, 2022
  • 17 locations
Pre Operative Trastuzumab in Operable Breast Cancer

single dose of Trastuzumab (Herceptin, Hoffman La Roche) at 8 mg/Kg as a 90 minute intravenous infusion in 250 ml of normal saline, in the window period of 10-15 4 to 14 days (both days inclusive) prior

trastuzumab
tumor cells
HER2
platelet count
gilbert's syndrome
  • 71 views
  • 14 May, 2022
  • 1 location
Biomarkers Investigation of Neoadjuvant Chemotherapy for Breast Cancer

positive HER-2, additional Herceptin could improve the response further. In this study the efficacy of combined neoadjuvant therapy with or without Herceptin should be evaluated and the role in predicting

trastuzumab
renal function test
mammogram
herceptin
MRI
  • 7 views
  • 21 Jan, 2021
  • 2 locations
Detect V / CHEVENDO (Chemo vs. Endo)

Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and

metastasis
trastuzumab
HER2
primary tumor
platelet count
  • 35 views
  • 08 Aug, 2022
  • 1 location
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases

>Trastuzumab (Herceptin®)

metastasis
trastuzumab
HER2
herceptin
her2/neu-positive breast cancer
  • 2 views
  • 16 Mar, 2022
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

This research study is studying a combination of drugs as a possible treatment for breast cancer. The drugs involved in this study are: Group A: Trastuzumab (Herceptin

metastasis
trastuzumab
tumor cells
primary tumor
HER2
  • 30 views
  • 21 Jul, 2022
  • 16 locations
MARGetuximab Or Trastuzumab (MARGOT) (MARGOT)

. Drugs and Combinations used: Paclitaxel, Pertzumab and Margetuximab (Margenza) Paclitaxel, Pertzumab and Trastuzumab (Herceptin)

trastuzumab
breast carcinoma
her-2
HER2
gilbert's syndrome
  • 19 views
  • 13 Jul, 2022
  • 15 locations
ATEMPT 2.0: Adjuvant T-DM1 vs TH

therapies as a treatment after surgery. The name of the study drugs involved are: Trastuzumab-emtansine (T-DM1, Kadcyla) Trastuzumab SC (Herceptin Hylecta)

trastuzumab
mastectomy
HER2
sentinel node
herceptin
  • 1 views
  • 10 Jul, 2022
  • 17 locations
Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI

The purpose of the study is to see if using an investigational drug called [18F]FMISO with PET/MRI imaging can help monitor and predict the effect of trastuzumab (Herceptin) on chemotherapy in

trastuzumab
HER2
primary tumor
breast cancer
herceptin
  • 0 views
  • 23 Mar, 2022
  • 1 location
A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020

of their activity based on antibody-dependent cell-mediated cytotoxicity (ADCC), mediated by natural killer (NK) cells. Trastuzumab (Herceptin®) is a recombinant DNA-derived humanized

trastuzumab
tumor cells
HER2
herceptin
pertuzumab
  • 0 views
  • 15 Jun, 2022
  • 1 location